These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23954707)

  • 1. Defining and characterizing drug/compound function.
    Kenakin T; Williams M
    Biochem Pharmacol; 2014 Jan; 87(1):40-63. PubMed ID: 23954707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fall and rise of pharmacology--(re-)defining the discipline?
    Winquist RJ; Mullane K; Williams M
    Biochem Pharmacol; 2014 Jan; 87(1):4-24. PubMed ID: 24070656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evasive nature of drug efficacy: implications for drug discovery.
    Galandrin S; Oligny-Longpré G; Bouvier M
    Trends Pharmacol Sci; 2007 Aug; 28(8):423-30. PubMed ID: 17659355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy.
    van der Westhuizen ET; Breton B; Christopoulos A; Bouvier M
    Mol Pharmacol; 2014 Mar; 85(3):492-509. PubMed ID: 24366668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional pathway pharmacology: chemical tools, pathway knowledge and mechanistic model-based interpretation of experimental data.
    Hendriks BS
    Curr Opin Chem Biol; 2010 Aug; 14(4):489-97. PubMed ID: 20609614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guide for calculating and representing biased signaling by GPCR ligands: A stepwise approach.
    Nagi K; Pineyro G
    Methods; 2016 Jan; 92():78-86. PubMed ID: 26364590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of drug-target residence time.
    Zhang R; Monsma F
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century.
    Kenakin T; Bylund DB; Toews ML; Mullane K; Winquist RJ; Williams M
    Biochem Pharmacol; 2014 Jan; 87(1):64-77. PubMed ID: 24269285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative versus qualitative data: the numerical dimensions of drug action.
    Bylund DB; Toews ML
    Biochem Pharmacol; 2014 Jan; 87(1):25-39. PubMed ID: 23933389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-receptor interaction platforms and their applications for drug discovery.
    Fang Y
    Expert Opin Drug Discov; 2012 Oct; 7(10):969-88. PubMed ID: 22860803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular determinants of drug-receptor binding kinetics.
    Pan AC; Borhani DW; Dror RO; Shaw DE
    Drug Discov Today; 2013 Jul; 18(13-14):667-73. PubMed ID: 23454741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular and systems levels.
    Yin N; Pei J; Lai L
    Mol Biosyst; 2013 Jun; 9(6):1381-9. PubMed ID: 23478789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational chemistry approaches to drug discovery in signal transduction.
    Fischer PM
    Biotechnol J; 2008 Apr; 3(4):452-70. PubMed ID: 18412174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and the drug-target residence time concept.
    Dahl G; Akerud T
    Drug Discov Today; 2013 Aug; 18(15-16):697-707. PubMed ID: 23500610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nature of efficacy at G protein-coupled receptors.
    Zhao P; Furness SGB
    Biochem Pharmacol; 2019 Dec; 170():113647. PubMed ID: 31585071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When simple agonism is not enough: emerging modalities of GPCR ligands.
    Smith NJ; Bennett KA; Milligan G
    Mol Cell Endocrinol; 2011 Jan; 331(2):241-7. PubMed ID: 20654693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery.
    Christopoulos A
    Nat Rev Drug Discov; 2002 Mar; 1(3):198-210. PubMed ID: 12120504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data.
    Bender A; Mikhailov D; Glick M; Scheiber J; Davies JW; Cleaver S; Marshall S; Tallarico JA; Harrington E; Cornella-Taracido I; Jenkins JL
    J Proteome Res; 2009 May; 8(5):2575-85. PubMed ID: 19271732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.